<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-19T13:48:39Z</responseDate><request verb="GetRecord" identifier="oai:openscholar.dut.ac.za:10321/5281" metadataPrefix="oai_dc">https://openscholar.dut.ac.za/server/oai/request</request><GetRecord><record><header><identifier>oai:openscholar.dut.ac.za:10321/5281</identifier><datestamp>2025-04-03T01:06:06Z</datestamp><setSpec>com_10321_11</setSpec><setSpec>col_10321_12</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Nephrotoxicity associated with preeclampsia in an Arginine Vasopressin induced rat pregnancy model</dc:title>
   <dc:creator>Ramdin, Sapna</dc:creator>
   <dc:contributor>Naicker, Thajasvarie</dc:contributor>
   <dc:contributor>Govender, Nalini</dc:contributor>
   <dc:subject>Preeclampsia</dc:subject>
   <dc:subject>Toxemia of pregnancy</dc:subject>
   <dc:subject>Preeclampsia</dc:subject>
   <dc:subject>Vasopressin</dc:subject>
   <dc:subject>Nephrotoxicology</dc:subject>
   <dc:description>Submitted in fulfillment of the requirements for the degree of Doctor of Philosophy: Health Sciences, Durban University of Technology, Durban, South Africa, 2022.</dc:description>
   <dc:description>Introduction: Globally, preeclampsia (PE) complicates an estimated 2-8% of&#xd;
pregnancies and is a leading cause of maternal and fetal morbidity and mortality. Renal&#xd;
injury is closely involved in the pathophysiology of PE and is associated with future risk&#xd;
of kidney disease. Identifying an early biomarker of renal dysfunction is essential for the&#xd;
diagnosis and treatment of PE. Given the clinical and ethical complexities associated&#xd;
with pregnancy studies in humans, animal models provide a more feasible alternative to&#xd;
pregnancy research.&#xd;
Aim: In view of this, this study aimed to determine the physiological and biochemical&#xd;
features of the arginine vasopressin (AVP) induced pregnancy model in the Sprague&#xd;
Dawley rat and to demonstrate nephrotoxicity associated with this model.&#xd;
Methodology: Urine, blood and kidney samples (n = 6 per study group) were collected&#xd;
from female Sprague Dawley rats, based on four study groups, viz., pregnant AVP,&#xd;
pregnant saline, non-pregnant AVP, and non-pregnant saline groups. The AVP rat model&#xd;
was physiologically characterized by evaluating the clinical, biochemical,&#xd;
haematological and fetal parameters across all study groups. Renal injury in AVP-treated&#xd;
rats was histologically determined by haematoxylin and eosin staining, as well as&#xd;
immunolocalizing kidney injury molecule-1 (KIM-1) and podocalyxin in both AVPtreated and untreated kidneys using immunohistochemistry. Ultrastructural changes in&#xd;
AVP-treated rats were determined by transmission electron microscopy. The Multiplex&#xd;
kidney toxicity immunoassay panels were used to determine the urinary concentration of&#xd;
albumin, vascular endothelial growth factor-A, clusterin, cystatin C, beta-2-&#xd;
microglobulin, KIM-1, neutrophil gelatinase-associated lipocalin-2, osteopontin and&#xd;
tissue inhibitor of metalloproteinases-1 in AVP-treated rats.&#xd;
Key findings: Chronic infusion of AVP throughout gestation reproduced the phenotypes&#xd;
viz., increased blood pressure, elevated urinary protein levels and fetal growth restriction,&#xd;
characteristic of human PE development. Immunohistochemical analysis confirm KIM1 immunolocalization in the proximal convoluted tubules of AVP-treated vs. untreated groups. Comparatively, a mild immunolocalization of podocalyxin was observed in the&#xd;
glomeruli of pregnant AVP-treated vs. pregnant untreated rats. Histological and&#xd;
ultrastructural evaluation of the AVP-treated pregnant rats demonstrated several&#xd;
abnormalities including, reduced Bowman’s space, necrosis of tubules and blood vessels,&#xd;
along with podocyte effacement, glomerular basement membrane abnormalities,&#xd;
podocyte nuclear crenations, mitochondrial dysfunction and cytoplasmic lysis consistent&#xd;
with renal injury in PE. Our findings indicate that AVP significantly reduces the urinary&#xd;
levels of vascular endothelial growth factor A and concomitantly up-regulates the urinary&#xd;
expression of clusterin, cystatin C, beta-2-microglobulin, KIM-1, neutrophil gelatinaseassociated lipocalin-2, osteopontin and tissue inhibitor of metalloproteinases-1.&#xd;
Conclusion: This is the first study to demonstrate that AVP induces glomerular and&#xd;
tubular injury, as well as endothelial dysfunction in the pregnant Sprague Dawley rat&#xd;
model. These features are characteristic of renal injury observed in PE. Furthermore,&#xd;
AVP successfully elevated the urinary levels of most glomerular and tubular injury&#xd;
biomarkers as well as produced histological and ultrastructural renal abnormalities&#xd;
associated with human PE. Our data demonstrates the importance of kidney injury as&#xd;
early detection biomarkers for PE development. The findings support the use of the AVP&#xd;
rat model in future studies investigating the pathogenic processes involved in PE&#xd;
development.</dc:description>
   <dc:description>D</dc:description>
   <dc:date>2024-04-29T09:45:02Z</dc:date>
   <dc:date>2024-04-29T09:45:02Z</dc:date>
   <dc:date>2023-05</dc:date>
   <dc:type>Thesis</dc:type>
   <dc:identifier>https://hdl.handle.net/10321/5281</dc:identifier>
   <dc:identifier>https://doi.org/10.51415/10321/5281</dc:identifier>
   <dc:language>en</dc:language>
   <dc:format>147 p</dc:format>
   <dc:format>application/pdf</dc:format>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>